Maintaining Access

EndoGI is transforming the traditional non-vascular stenting market, focusing on the endoscopic gastro-ERCP space..

 Innovative, safe and affordable, EndoGI’s Single & Multiple stent delivery systems assists in reducing cost, procedure time, steps – as  well as associated complications – in biliary and pancreatic stent placement procedures.

EndoGI has received two different FDA marketing clearances-510 (k) regulatory approvals on single and multiple stent and delivery system and has launched initial post regulatory approval clinical studies- First in Human.

Easy To Use

Reduced complications

Less Time & Procedure Steps

Fewer Risks

Frequently Asked Questions

EndoGI privately-owned Israeli company, backed by NGT3VC. EndoGI develops Stenting Placement Delivery Systems for the treatment of biliary and pancreatics stenosis and strictures in one cannulation while keeping the guide wire in place lateral after stent deployment.

       EndoGI has received two different FDA marketing clearances-510 (k) regulatory approvals on single and multiple stent and delivery system and has launched initial post regulatory approval clinical studies- First in Human.

Status Updates & Articles

for more articles & updates>>